Intelligent Bio Solutions completes usability study for FDA filing of codeine fingerprint drug test
INBS•Planned submission in 2026
The milestone supports a planned 510(k) submission in H2 2026, a key step toward U.S. market entry.
Study results support workplace use
Results were presented now, with the study indicating non-specialist workplace operators could be trained to run tests accurately.
Usability study completed for FDA 510(k) filing
Intelligent Bio Solutions completed a usability study backing an FDA 510(k) filing for its fingerprint-based drug screening system targeting codeine detection.
